Apheris logo
Menu

About Apheris

Apheris powers the world’s leading federated life sciences data networks, addressing the critical challenge of accessing proprietary data locked in silos due to IP and privacy concerns.

The Apheris product is used by some of the largest global life sciences organizations to collaborate on sensitive, proprietary data across teams, borders, and organizations.

Our customers unlock the value of complementary data and collaboratively train machine learning models on their distributed datasets to improve accuracy and generalizability to meet the precision required for industrial settings.

Meet our Founders

Robin Röhm

Co-Founder & CEO

Robin studied medicine, philosophy and mathematics and was trained in global banking at UBS. In one of his previous start-ups, he lost multiple customers as data couldn’t be centralized due to regulatory constraints. He is driving the vision, strategy, and culture of Apheris.​

Michael Höh

Co-Founder & CTO

Michael has a PhD in physics and computer science. He was trained at BCG where he built digital solutions and AI applications for industrial clients. As CTO he leads our platform architecture and design, our engineering target picture, technical customer commitments and legal and contractual scoping.​

Events we're joining

September
10-11
Drug Discovery Innovation Forum
Barcelona

Our VP of Product, Ellie Dobson, will speak about fine-tuning OpenFold3 on proprietary pharma data - bridging the gab between today's algorithmic capabilities and complex industrial demands

September
17th
NVIDIA FLARE Day
Online Event

Robin Röhm, and Markus Bujotzek will present a privacy-preserving federated clustering framework protecting each partner's IP. Our method combines clustering algorithms evaluated on drug discovery data with a secure translation into a federated setting, implemented using the NVIDIA FLARE framework.

September
22nd
8th Artificial Intelligence in Chemistry Symposium
Churchill College, Cambridge

Excited to join the AI in Chemistry Symposium to learn about the latest industry breakthroughs and connect with leading experts in structural drug discovery and ADMET modeling.

October
14th
FLTA25
Dubrovnik

To explore molecular data diversity for drug development in federated settings, we benchmarked clustering methods (Fed-kMeans, Fed-PCA+Fed-kMeans, Fed-LSH) on eight datasets, evaluating results with quantitative, qualitative, and domain-specific metrics.

November
9th
Protein Structure Determination in Industry (PSDI)
Basel

Our CEO, Robin Röhm, will present how the AISB Network addresses the scarcity of public protein-ligand structure data through secure, collaborative AI model training. We’ll present the experimental setup, federated learning infrastructure, IP protection, and collaborative training results of our first initative.

Our culture is based upon our core values

Impact

We are driven by impact and strive for the impossible

Collaboration

Through collaboration, we create a whole that is far greater than the sum of its parts

Responsibility

We are responsible together and commit to ownership

Humility

We have the humility and hunger to learn

We’re looking for diverse and talented people

Check out our latest vacancies

Backed by top investors

Ross Mason
Founder of Mulesoft - Angel investor
Visit his LinkedIn
Mirko Novakovic
Founder of Instana & Angel investor
Visit his LinkedIn
Patrick Pichette
Former CFO of Google & Angel investor
Visit his LinkedIn
Torsten Reil
Founder of Helsing & Angel investor
Visit his LinkedIn
Ian Hogarth
Chair UK Government's AI Foundation & angel investor
Visit his LinkedIn